80 related articles for article (PubMed ID: 32853216)
1. Long-term protection of HPV test in women at risk of cervical cancer.
Ibáñez R; Roura E; Monfil L; Rodríguez LA; Sardà M; Crespo N; Pascual A; Martí C; Fibla M; Gutiérrez C; Lloveras B; Oliveras G; Torrent A; Català I; Bosch FX; Bruni L; de Sanjosé S
PLoS One; 2020; 15(8):e0237988. PubMed ID: 32853216
[TBL] [Abstract][Full Text] [Related]
2. Protecting the underscreened women in developed countries: the value of HPV test.
Ibáñez R; Autonell J; Sardà M; Crespo N; Pique P; Pascual A; Martí C; Fibla M; Gutiérrez C; Lloveras B; Moreno-Crespi J; Torrent A; Baixeras N; Alejo M; Bosch FX; de Sanjosé S
BMC Cancer; 2014 Aug; 14():574. PubMed ID: 25102758
[TBL] [Abstract][Full Text] [Related]
3. Cervical Cancer Screening With Human Papillomavirus DNA and Cytology in Japan.
Sasaki Y; Iwanari O; Arakawa I; Moriya T; Mikami Y; Iihara K; Konno R
Int J Gynecol Cancer; 2017 Mar; 27(3):523-529. PubMed ID: 27997455
[TBL] [Abstract][Full Text] [Related]
4. Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China.
Zhang L; Xu XQ; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Feng RM; Dong L; Zhang Q; Ma JF; Sauvaget C; Zhao FH; Qiao YL; Sankaranarayanan R
Gynecol Oncol; 2018 Nov; 151(2):221-228. PubMed ID: 30269870
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial.
Winer RL; Lin J; Tiro JA; Miglioretti DL; Beatty T; Gao H; Kimbel K; Thayer C; Buist DSM
JAMA Netw Open; 2019 Nov; 2(11):e1914729. PubMed ID: 31693128
[TBL] [Abstract][Full Text] [Related]
6. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
7. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.
Ogilvie GS; Krajden M; van Niekerk D; Smith LW; Cook D; Ceballos K; Lee M; Gentile L; Gondara L; Elwood-Martin R; Peacock S; Stuart G; Franco EL; Coldman AJ
Int J Cancer; 2017 Jan; 140(2):440-448. PubMed ID: 27685757
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer screening cotesting with cytology and MRNA HPV E6/E7 yields high rates of CIN2+ lesions in young women.
Granados R; Tellez-Safina H; Solis I; Mateos F; Rodriguez-Barbero JM; Aramburu JA; Huertas MA; Bajo P; Camarmo E; Corrales T; Medina P; Calvo B; Martin E; Anta L; Zamora M; Alcaide T
Diagn Cytopathol; 2017 Dec; 45(12):1065-1072. PubMed ID: 28949442
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
Dong L; Wang MZ; Zhao XL; Feng RM; Hu SY; Zhang Q; Smith JS; Qiao YL; Zhao FH
Gynecol Oncol; 2018 Jan; 148(1):103-110. PubMed ID: 29169614
[TBL] [Abstract][Full Text] [Related]
10. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
[TBL] [Abstract][Full Text] [Related]
12. Evidence of decreased long-term risk of cervical pre-cancer after negative primary HPV screens compared to negative cytology screens in a longitudinal cohort study.
Gottschlich A; Hong Q; Gondara L; Alam MS; Cook DA; Martin RE; Lee M; Melinikow J; Peacock S; Proctor L; Stuart G; Franco EL; Krajden M; Smith LW; Ogilvie GS
Cancer Epidemiol Biomarkers Prev; 2024 May; ():. PubMed ID: 38773687
[TBL] [Abstract][Full Text] [Related]
13. Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases.
Gök M; Rozendaal L; Berkhof J; Visser O; Meijer CJ; van Kemenade FJ
Br J Cancer; 2011 Feb; 104(4):685-92. PubMed ID: 21266976
[TBL] [Abstract][Full Text] [Related]
14. Follow-up of women screened for cervical cancer in São Paulo, Brazil: An analysis of the times to diagnostic investigation and treatment.
Madalena Ribeiro C; Dos Santos Silva I; Eluf Neto J; Pereira Baltar Cury LC; Azevedo E Silva G
Cancer Epidemiol; 2021 Jun; 72():101940. PubMed ID: 33906100
[TBL] [Abstract][Full Text] [Related]
15. Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.
Cheung LC; Pan Q; Hyun N; Schiffman M; Fetterman B; Castle PE; Lorey T; Katki HA
Stat Med; 2017 Sep; 36(22):3583-3595. PubMed ID: 28660629
[TBL] [Abstract][Full Text] [Related]
16. Sample-weighted semiparametric estimation of cause-specific cumulative risk and incidence using left- or interval-censored data from electronic health records.
Hyun N; Katki HA; Graubard BI
Stat Med; 2020 Aug; 39(18):2387-2402. PubMed ID: 32390254
[TBL] [Abstract][Full Text] [Related]
17. Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.
Landy R; Cheung LC; Schiffman M; Gage JC; Hyun N; Wentzensen N; Kinney WK; Castle PE; Fetterman B; Poitras NE; Lorey T; Sasieni PD; Katki HA
Prev Med; 2018 Jun; 111():429-435. PubMed ID: 29222045
[TBL] [Abstract][Full Text] [Related]
18. Managing an extension of screening intervals: Avoiding boom and bust in health care workloads.
Pesola F; Rebolj M; Sasieni P
Int J Cancer; 2023 May; 152(10):2061-2068. PubMed ID: 36691808
[TBL] [Abstract][Full Text] [Related]
19. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.
Bonde J; Floore A; Ejegod D; Vink FJ; Hesselink A; van de Ven PM; Valenčak AO; Pedersen H; Doorn S; Quint WG; Petry KU; Poljak M; Stanczuk G; Cuschieri K; de Sanjosé S; Bleeker M; Berkhof J; Meijer CJLM; Heideman DAM
Int J Cancer; 2021 Jan; 148(2):396-405. PubMed ID: 32997803
[TBL] [Abstract][Full Text] [Related]
20. Correction: Long-term protection of HPV test in women at risk of cervical cancer.
PLOS ONE Staff
PLoS One; 2020; 15(11):e0243000. PubMed ID: 33216813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
